Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Nov;1005:423-30.
doi: 10.1196/annals.1288.072.

Prevention of Autoimmune Diabetes Through Immunostimulation With Q Fever Complement-Fixing Antigen

Affiliations
Clinical Trial

Prevention of Autoimmune Diabetes Through Immunostimulation With Q Fever Complement-Fixing Antigen

D G Silva et al. Ann N Y Acad Sci. .

Abstract

The most promising strategies for prevention of type 1 diabetes seem to be in the categories of immunomodulation (e.g., nondepleting anti-CD3, Diapep, linomide) and/or immunostimulation (e.g., QFA, BCG). We are currently undertaking a research program directed toward better understanding of immunostimulants to help maximize the likelihood of success of future human clinical trials for diabetes prevention. This program is focused on the key areas of optimization of vaccine dose and route of administration, development of surrogate immune markers, and elucidation of the mechanism of protection. The mechanism whereby QFA protects against diabetes currently is not known. The elucidation of the mechanism should help identify the optimal way in which to administer QFA to provide diabetes protection. It may also assist the development of even more potent immunostimulatory vaccines.

Similar articles

See all similar articles

Cited by 2 articles

Publication types

LinkOut - more resources

Feedback